180 Life Sciences Corp. has filed a prospectus supplement with the SEC, updating and amending its previous prospectus dated May 12, 2023. The supplement includes information from Current Reports filed on various dates from December 2023 to February 2024, and details an extension and reduction in the exercise price of certain common stock purchase warrants. The company's common stock is traded on Nasdaq under the symbol 'ATNF', with a last reported sale price of $0.21 per share as of February 15, 2024. The company has been involved in a series of corporate actions, including a repricing and extension of warrants, compliance with Nasdaq Listing Rule 5635(d), and amendments to executive compensation agreements. These actions were taken in response to a notice from Nasdaq regarding non-compliance with shareholder approval requirements and to address the company's stockholders' equity deficit. Additionally, the company has engaged a financial advisor to explore strategic alternatives to enhance shareholder value. The date of the latest prospectus supplement is February 16, 2024.

180 Life Sciences Corp. has filed a prospectus supplement with the SEC, updating and amending its previous prospectus dated May 12, 2023. The supplement includes information from Current Reports filed on various dates from December 2023 to February 2024, and details an extension and reduction in the exercise price of certain common stock purchase warrants. The company's common stock is traded on Nasdaq under the symbol 'ATNF', with a last reported sale price of $0.21 per share as of February 15, 2024. The company has been involved in a series of corporate actions, including a repricing and extension of warrants, compliance with Nasdaq Listing Rule 5635(d), and amendments to executive compensation agreements. These actions were taken in response to a notice from Nasdaq regarding non-compliance with shareholder approval requirements and to address the company's stockholders' equity deficit. Additionally, the company has engaged a financial advisor to explore strategic alternatives to enhance shareholder value. The date of the latest prospectus supplement is February 16, 2024.